WA-ECHODYNE
12.10.2021 14:02:08 CEST | Business Wire | Press release
Echodyne , the radar platform company, announced today the newest addition to its market-leading portfolio of radars - EchoShield. Designed from the ground-up to set a new price-performance standard for mid-range radars, EchoShield is an advanced software-defined multi-mission radar for a wide variety of commercial, defense, and government use cases.
EchoShield’s development has been informed by hundreds of customers and applications across multiple industries. The radar’s architecture builds upon the field-proven success of Echodyne’s proprietary metamaterials electronically scanned array (MESA®) radars that are in use across a wide range of applications, such as counter-UAS, border and base security, force protection, critical infrastructure security, intelligence, surveillance, and reconnaissance, UAV detect and avoid, and autonomous ground vehicles.
A pulse-Doppler cognitive 4D radar, EchoShield combines ultra-precise electronically scanned array (ESA) beamforming and real-time dynamic waveform synthesis to deliver sub-degree tracking accuracy on hundreds of objects across a broad 3D field of view. EchoShield’s cognitive search capabilities integrate onboard or offboard data stores to adapt and direct radar resources when and where required in order to deliver the right data and detail at the right time. Whether using the radar’s significant onboard processing capabilities or ingesting data-rich range-doppler spectrograms into offboard compute, EchoShield’s SDK enables deep integration and multi-sensor fusion.
EchoShield is designed to be software-optimized to mission profiles that align powerful dynamic radar resources with unique customer requirements to deliver superior radar performance. Based on market demand, the initial software release prioritizes a counter-UAS mission and excels at detecting, tracking, and classifying any uncrewed aircraft, including low slow and small drones even in dense urban environments. Further releases will match radar resources with customer demand in dozens of applications and markets.
“Radar is a fundamental sensor for a wide range of commercial and government applications, but achieving high performance at reasonable cost, size, weight and power (C-SWaP) has always been a challenge,” said Eben Frankenberg, CEO of Echodyne. “Our customers have challenged us with certain radar performance attributes and EchoShield has been designed to meet these demanding requirements. Our customers are lining up for first units and already discussing production volume, so we’re very pleased with the market reception.”
EchoShield is designed to operate in the Ku band, with radiolocation service at 15.7-16.6 GHz and radionavigation at 15.4-15.7 GHz, and is commercially exportable. Its features include:
- 130° azimuth x 90° elevation field of regard (fully customizable)
- 0.5° tracking accuracy in azimuth and elevation, with very low track splitting/dropping
- Powerful UAV classification with low false-alarms and near-zero false-negatives
- Cognitive search capabilities integrate onboard or offboard data
-
Average tracking ranges for counter-UAS mission:
- Group 1 (-20 to -10 dBsm): 2.7 to 4.8 km
- Group 2 (-10 to -5 dBsm): 4.8 to 6.4 km
- Group 3 (-5 to 5 dBsm): 6.4 to 11.4 km
“Our breakthrough Metamaterial-ESA technology unlocks a level of beamforming previously only available with large ultra-expensive AESA’s with hundreds of channels,” said Tom Driscoll, CTO of Echodyne. “EchoShield combines this precise beamforming with modern fully-adaptive cognitive-radar approaches and intelligent control software, and the result is a radar with best-in-class detection, tracking, and classification performance.”
For additional details and technical specifications, please visit our website at echodyne.com .
This device has not been authorized as required by the rules of the Federal Communications Commission. This device is not, and may not be, offered for sale or lease, or sold or leased, until authorization is obtained.
About Echodyne
Echodyne , the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically scanned array radars are used by defense and government agencies, autonomous developers, and security integrators for counter-UAS, borders and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Vulcan Capital, Vanedge Capital, and Lux Capital among others. For more information, please visit: Echodyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
